Advancing therapeutics using antibody-induced dimerization of receptor tyrosine phosphatases.
Genes Dev
; 37(15-16): 678-680, 2023 08 01.
Article
en En
| MEDLINE
| ID: mdl-37673461
ABSTRACT
Receptor protein tyrosine phosphatases (RPTPs) are involved in a broad list of cellular, developmental, and physiological functions. Altering their expression leads to significant changes in protein phosphorylation linked to a growing list of human diseases, including cancers and neurological disorders. In this issue of Genes & Development, Qian and colleagues (pp. 743-759) present the identification of a monoclonal antibody targeting PTPRD extracellular domain-inducing dimerization and inhibition of the phosphatase activities, causing the proteolysis of dimeric PTPRD by a mechanism involving intracellular degradation pathways. Their study supports the potential of modulating PTPRD via its extracellular domains. This opens a new framework in the clinical manipulation of PTPRD and its closely related family members.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Inmunoglobulinas
/
Proteínas Tirosina Fosfatasas
Límite:
Humans
Idioma:
En
Año:
2023
Tipo del documento:
Article